Disney World's Top Park Has a New $649 Treat

Disney World's Top Park Has a New $649 Treat

There’s a new way to splurge at Disney‘s (NYSE:DIS) largest and most expensive Florida theme park. Disney’s Magic Kingdom — the only theme park in the planet to have entertained more than 20 million guests last year — is adding Kingdom Cabanas to its arsenal of upsell products.  Theme park blog WDW News Today is reporting that → Read More

Shareholder Dilution: What Investors Need to Know

Shareholder Dilution: What Investors Need to Know

This podcast was recorded on Nov. 16, 2016. Kristine Harjes: Welcome to Industry Focus, the podcast that dives into a different sector of the stock market everyday. It’s Nov. 16. I’m your host, Kristine Harjes, and I am pleased to welcome Financials host Gaby Lapera in the studio for crossover week. Hi, Gaby! Gaby Lapera: → Read More

3 Attractive Income Stocks Whose Dividends Could Double

3 Attractive Income Stocks Whose Dividends Could Double

Dividend stocks can be the foundation of a great retirement portfolio. Not only do the payments put money in your pocket, which can help hedge against any dips in the stock market, but they’re usually a sign of a financially sound company. Dividends also give investors a painless opportunity to reinvest in a stock, thus → Read More

ETF Fees Race Toward Zero

ETF Fees Race Toward Zero

Management fees are plummeting toward zero. BlackRock (NYSE:BLK) recently slashed fees on 15 of its exchange-traded funds, a move that an executive described as being part of its plan to manage the single largest ETF in existence. Charles Schwab (NYSE:SCHW) responded by slashing fees on some of its funds to reclaim its title of having → Read More

Will This Franchise Lead Celgene To Over $20 Billion in Revenue?

Will This Franchise Lead Celgene To Over $20 Billion in Revenue?

Celgene (NASDAQ:CELG) has done what many biotechs can only dream of: establish itself as a major player in oncology with one of the best-selling drugs in the industry.  . This drug, Revlimid, anchors the company’s hematology business with over $6 billion in revenue and the possibility of further label extensions. While $6 billion sounds impressive, → Read More

The Polaris Slingshot Could Be in Real Trouble

The Polaris Slingshot Could Be in Real Trouble

The three-wheel Polaris Industries (NYSE:PII) Slingshot motorcycle has been a hit ever since it was first introduced, helping the powersports vehicle maker boost segment revenue by double-digit rates. While most of the gains were due to the popularity of its Indian Motorcycle brand, the trike has had its fair share of increasing sales, too. But now, two → Read More

SINA Corporation Posts Another Solid Quarter

SINA Corporation Posts Another Solid Quarter

  SINA Corporation (NASDAQ:SINA) announced third-quarter 2016 results Monday after the market closed, and shares of the the Chinese online media company are up 2% in after-hours trading as of this writing. Let’s take a closer look at what drove SINA’s business this quarter. SINA’s results: The raw numbers Metric Q3 2016 Q3 2015 Year-Over-Year Change GAAP → Read More

The Most Important Homeownership Chart You'll Ever See

The Most Important Homeownership Chart You'll Ever See

To be perfectly clear from the start, I’m a big advocate of homeownership. I own my own home, and have written before about all the reasons to buy a home. I simply believe that for many people, owning a home is a smart financial decision and here’s why. The financial benefits of owning a home → Read More

Trump backs out of meeting with New York Times

Trump backs out of meeting with New York Times

Trump versus ‘New York City media’ President-elect Donald Trump backed out of a meeting he had called with The New York Times on Tuesday, saying on Twitter that the “terms and conditions” were changed at the last minute. “Not nice,” Trump said in an early morning tweet. He called the newspaper “failing,” a favorite insult. → Read More

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.